Vector planet earth with flickering lights overlayed with blue/orange gradient.
NEWS & INVESTORS

Stay up-to
-date with
Marengo.

Featuring data from our lead program, STAR0602.

  • Creating a new category of PD-1 independent IO medicines
  • LEARN MORE HERE
  • Establishing strategic partnerships to advance our novel, selective T cell activators
  • LEARN MORE HERE
  • Advancing Lead Asset, STAR0602, into human trials for PD-1 refractory solid tumors
  • READ THE PRESS RELEASE
    • STAR0602 reinvigorates T cell compartments in tumors to promote durable, long-term protection against cancer.

    News

    • All news
    • In the news
    • Press releases
    Load More

    Conferences

    Attending
    Presenting

    Presentations

    • All resources
    • Presentations
    Load More
    Investors
    Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives.
    APPLETREEPARTNERS.COM